Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SERA PROGNOSTICS, INC.
Report date March 12, 2026 · Filed May 06, 2026
Section 16 reporting ended · disclosed 2026-05-06. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2022 Filed Jun 1, 2022 21:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $1.45 | $3,951.25 |
DisclosureSEC source: 0001534969-22-000076 · wf-form4_165411969787689.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,310 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.49, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 24, 2022 Filed May 24, 2022 22:16 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $1.54 | $4,196.50 |
DisclosureSEC source: 0001534969-22-000074 · wf-form4_165343056027334.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,035 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2022 Filed May 17, 2022 22:41 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $1.55 | $4,223.75 |
DisclosureSEC source: 0001534969-22-000072 · wf-form4_165282724384796.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,760 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.64, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2022 Filed May 10, 2022 22:47 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $1.97 | $5,368.25 |
DisclosureSEC source: 0001534969-22-000070 · wf-form4_165222284201007.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,485 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. Read SEC document |
| May 04, 2022 Filed May 4, 2022 22:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · derivative · entry 3 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 Underlying: Class A Common Stock · 1,000 shares Expires 2022-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| May 04, 2022 Filed May 4, 2022 22:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 1,000 | $2.17 | $2,170.00 |
DisclosureSEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · nonDerivative · entry 2 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,210 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.11 to $2.30, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 4, 2022 22:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionClass A Common Stock | 1,000 | $0.73 | $730.00 |
DisclosureSEC source: 0001534969-22-000064 · wf-form4_165170239136811.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 3, 2022 21:43 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $2.17 | $5,913.25 |
DisclosureSEC source: 0001534969-22-000062 · wf-form4_165161417543531.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,210 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.12 to $2.23, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2022 Filed Apr 26, 2022 22:28 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $2.17 | $5,913.25 |
DisclosureSEC source: 0001534969-22-000060 · wf-form4_165101209655230.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,935 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.31, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 20:36 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $2.08 | $5,668.00 |
DisclosureSEC source: 0001534969-22-000054 · wf-form4_165048695567483.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,660 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.21, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 20:26 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $2.66 | $7,248.50 |
DisclosureSEC source: 0001534969-22-000052 · wf-form4_164988158779641.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,385 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.84, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:09 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · derivative · entry 4 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,844 Underlying: Class A Common Stock · 1,000 shares Expires 2022-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:09 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 1,000 | $3.02 | $3,020.00 |
DisclosureSEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 3 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,110 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $3.19, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:09 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionClass A Common Stock | 1,000 | $0.73 | $730.00 |
DisclosureSEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 2 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:09 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $3.35 | $9,128.75 |
DisclosureSEC source: 0001534969-22-000044 · wf-form4_164936217180631.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,110 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.53, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 20:07 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $3.73 | $10,164.25 |
DisclosureSEC source: 0001534969-22-000038 · wf-form4_164867081882345.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,835 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 20:34 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 121,705 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001534969-22-000020 · wf-form4_164824045068286.xml · derivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,705 Underlying: Class A Common Stock · 121,705 shares Expires 2032-03-23 F1 · derivative.exercise_date: These stock options vest over four years beginning on the grant date of March 23, 2022 as follows: 15% of the original grant amount vests in equal monthly installments over the first year following the grant date, 20% of the original grant amount vests in equal monthly installments over the second year following the grant date, 25% of the original grant amount vests in equal monthly installments over the third year following the grant date, and 40% of the original grant amount vests in equal monthly installments over the fourth year following the grant date, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:11 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $3.68 | $10,028.00 |
DisclosureSEC source: 0001534969-22-000010 · wf-form4_164806629160651.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,560 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.82, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 21:58 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 2,725 | $3.94 | $10,736.50 |
DisclosureSEC source: 0001534969-22-000008 · wf-form4_164738149272802.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,285 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:16 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionStock Option (right to buy) · Derivative | 75,998 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001534969-22-000006 · wf-form4_164728880705549.xml · derivative · entry 2 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 75,998 shares Expires 2022-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:16 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionClass A Common Stock | 75,998 | $0.73 | $55,478.54 |
DisclosureSEC source: 0001534969-22-000006 · wf-form4_164728880705549.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 02:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionStock Option (right to buy) · Derivative | 25,012 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001534969-21-000027 · wf-form4_163884334581990.xml · derivative · entry 2 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,012 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 02:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionClass A Common Stock | 25,012 | $0.73 | $18,258.76 |
DisclosureSEC source: 0001534969-21-000027 · wf-form4_163884334581990.xml · nonDerivative · entry 1 Boniface John J. · CIK 0001870674 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.